Latest Biotech News

GRWD5769, a first-in-class oral ERAP1 inhibitor, paired with cemiplimab generated durable responses across six completed phase 1b expansion cohorts in patients with secondary resistance to...

Pfizer’s next monthly obesity strategy, berobenatide, continued to show ongoing weight loss dynamics as patients transitioned from weekly dosing to monthly dosing in the VESPER-3 study. Data...

Abivax’s stock reaction to positive phase 3 results in ulcerative colitis sharpened around a malignancy signal flagged by analysts, underscoring how safety interpretation can rapidly alter...

Boehringer Ingelheim’s obesity asset survodutide faced renewed scrutiny after phase 3 updates at ADA26 showed a notably elevated discontinuation rate due to side effects. The reporting tied...

Researchers reported that anisodine can block vasogenic cerebral edema in an ischemic stroke therapeutic context, targeting mechanisms tied to edema that can arise after delayed administration of...

A new radar-based, contactless movement monitoring system is designed to detect early motor irregularities in outpatient pediatric settings without requiring sensors or overt clinical...

A new industry analysis argues that biopharma’s competitive advantage is shifting from pure innovation toward operational capability—specifically the ability to translate scientific progress into...

A nuclear medicine logistics report details why scaling radiopharmaceutical supply chains is fundamentally different from standard cold-chain drug distribution. It describes how radioactive decay...

An observational study published in Annals of Oncology reported that weight loss medications, particularly GLP-1 receptor agonists, were associated with a reduced risk of obesity-related cancers...

Eli Lilly shared additional safety and tolerability data on its next-generation obesity drug retatrutide, highlighting arrhythmia and major cardiovascular event rates in a late-stage dataset. The...

Pfizer broadened the clinical case for its monthly obesity GLP-1 treatment berobenatide with new mid-stage data on a weekly-to-monthly dosing path. The company’s data were presented at the...

Roche said it plans to start a Phase 2 trial this year testing an obesity-drug combination of petrelintide and enicepatide. The company framed the pairing as an opportunity to combine a...

Abivax’s shares swung after the company’s Phase 3 ABTECT maintenance trial posted positive topline results for obefazimod in ulcerative colitis, but investors focused on malignancies seen in...

GRWD5769, an oral ERAP1 inhibitor, combined with cemiplimab showed durable activity across multiple Phase 1b expansion cohorts in solid tumors with secondary anti–PD-1 resistance and in MSS-CRC....

Pfizer presented data indicating berobenatide’s long-acting monthly GLP-1 regimen delivers efficacy in patients with both obesity and diabetes, reinforcing the drug’s positioning after its Metsera...

A German observational analysis using health insurance claims data linked discontinuation of dental care to worsening systemic diseases in homebound elderly patients. Published under the InSEMaP...

Researchers engineered a portable CRISPR-based assay for mpox detection designed for field use following the 2025 outbreak in Sierra Leone. The work, led by Gopal, Abay, and Payne, aims to improve...

ABBV-706, a SEZ6-targeting antibody-drug conjugate, began first-in-human evaluation in patients with advanced solid tumors. The clinical update is logged in a Journal of Clinical Oncology...

A new saliva-based biomarker strategy is being advanced for oral potentially malignant disorders, with reported links between oral precancer status and clinical outcomes. The study, led by Chen...

Boehringer Ingelheim’s obesity shot, survodutide (licensed from Zealand Pharma), saw notable Phase 3 discontinuations attributed to side effects, according to SYNCHRONIZE-1 reporting referenced in...